Abstract:Background Our previous studies revealed a critical role of a novel CTLA4-protein kinase C-eta (PKCη) signaling axis in mediating the suppressive activity of regulatory T cells (Tregs) in antitumor immunity. These studies have employed adoptive transfer of germline PKCη-deficient ( Prkch −/− ) Tregs into Prkch +/+ mice prior to tumor implantation. Here, we extended these findings into a biologically and clinically more relevant context. Methods We have analyzed the role of PKCη in antitumor immunity and the tumor microenvironment (TME) in intact tumor-bearing mice with Treg-specific or CD8 + T cell-specific Prkch deletion, including in a therapeutic model of combinatorial treatment. In addition to measuring tumor growth, we analyzed the phenotype and functional attributes of tumor-infiltrating immune cells, particularly Tregs and dendritic cells (DCs). Results Using two models of mouse transplantable cancer and a genetically engineered autochthonous hepatocellular carcinoma (HCC) model, we found, first, that mice with Treg-specific Prkch deletion displayed a significantly reduced growth of B16–F10 melanoma and TRAMP-C1 adenocarcinoma tumors. Tumor growth reduction was associated with a less immunosuppressive TME, indicated by increased numbers and function of tumor-infiltrating CD8 + effector T cells and elevated expression of the costimulatory ligand CD86 on intratumoral DCs. In contrast, CD8 + T cell-specific Prkch deletion had no effect on tumor growth or the abundance and functionality of CD8 + effector T cells, consistent with findings that Prkch −/− CD8 + T cells proliferated normally in response to in vitro polyclonal or specific antigen stimulation. Similar beneficial antitumor effects were found in mice with germline or Treg-specific Prkch deletion that were induced to develop an autochthonous HCC. Lastly, using a therapeutic model, we found that monotherapies consisting of Treg-specific Prkch deletion or vaccination with irradiated Fms-like tyrosine kinase 3 ligand (Flt3L)-expressing B16–F10 tumor cells post-tumor implantation significantly delayed tumor growth. This effect was more pronounced in mice receiving a combination of the two immunotherapies. Conclusion These findings demonstrate the potential utility of PKCη inhibition as a viable clinical approach to treat patients with cancer, especially when combined with adjuvant therapies.

The PTEN Pathway in Tregs is a Critical Driver of the Suppressive Tumor Microenvironment

PTENα functions as an immune suppressor and promotes immune resistance in PTEN-mutant cancer

Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression

Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

Peripheral-derived regulatory T cells contribute to tumor-mediated immune suppression in a nonredundant manner

Regulatory T cells crosstalk with tumor and endothelium through lymphotoxin signaling

Supplementary Figure S5 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

PTEN Directs Developmental and Metabolic Signaling for Innate-Like T Cell Fate and Tissue Homeostasis.

Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis

Supplementary Figure S1 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

PI3Kβ controls immune evasion in PTEN-deficient breast tumours

Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy

PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism

Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy

Tumor Microenvironment Dictates Function of Tumor-Expressed PD-L1

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment

Precise Spatiotemporal Interruption of Regulatory T-cell-Mediated CD8(+) T-cell Suppression Leads to Tumor Immunity

PPARδ restrains the suppression function of intra-tumoral Tregs by limiting CIITA-MHC II expression

Supplementary Figure S2 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy